A Phase 4 interventional study of Pitavastatin and Atorvastatin in Hypercholesterolemia With Type2DM, sponsored by JW Pharmaceutical. Completed. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 14th largest by enrollment, is one of 3 that started in 2008, is one of 8 in phase 4, and was the 14th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 25 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2008.
This study's enrollment of 161 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
JW Pharmaceutical has 9 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
To evaluate the effect of pitavastatin compared to atorvastatin on the change of Lipid profiles, ApoA1, ApoB, adiponectin and baPWV as a marker of atherosclerosis in Type 2DM .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pitavastatin
Drug: Atorvastatin
Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
Also known as: Livalo
Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
Also known as: Lipitor
Proportion of Patients Achieving LDL- C<100mg/dL
compare the proportion of patients achieving LDL- C\<100mg/dL
Time frame: After 16wk drug administration
The Change of LDL-C
The change of LDL-C between at 16-week and baseline
Time frame: After 16wk drug administration
| Milestone | Pitavastatin Group | Atorvastatin Group |
|---|---|---|
| Started | 83 | 78 |
| Completed | 58 | 43 |
| Not completed | 25 | 35 |
compare the proportion of patients achieving LDL- C\<100mg/dL
| Participants | Pitavastatin Group | Atorvastatin Group |
|---|---|---|
| Proportion of Patients Achieving LDL- C<100mg/dL | 61 | 54 |
The change of LDL-C between at 16-week and baseline
| mg/dl | Pitavastatin Group | Atorvastatin Group |
|---|---|---|
| The Change of LDL-C | -69.8 ± 22.5 | -70.9 ± 28.2 |
Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin Group | 0/81 (0%) | 0/81 (0%) | 3/81 (3.7%) |
| Atorvastatin Group | 0/70 (0%) | 0/70 (0%) | 0/70 (0%) |
| Event | Pitavastatin Group | Atorvastatin Group |
|---|---|---|
| coughingRespiratory, thoracic and mediastinal disorders | 3/81 | 0/70 |
| Age, Continuous(years) | Pitavastatin Group | Atorvastatin Group | Total |
|---|---|---|---|
| Mean | 59.6 (35.0 to 74.0) | 59.1 (41.0 to 74.0) | 59.3 (35 to 74) |
| Sex: Female, Male(Participants) | Pitavastatin Group | Atorvastatin Group | Total |
|---|---|---|---|
| Female | 55 | 54 | 109 |
| Male | 28 | 24 | 52 |
| Race and Ethnicity Not Collected(Participants) | Pitavastatin Group | Atorvastatin Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Pitavastatin Group | Atorvastatin Group | Total |
|---|---|---|---|
| South Korea | 83 | 78 | 161 |
No study locations are listed for this record.
The record gives a start of Apr 2008, a primary completion of May 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2019, 10 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin